Elizabeth Plimack, MD

Key Takeaways in the Treatment of Advanced RCC From KCRS 2023

October 27th 2023

Robert Motzer, MD, and Elizabeth Plimack, MD, discuss clinical findings in the treatment of advanced RCC from the recent KCRS 2023 meeting, emphasizing the significance of circulating tumor cells, advances in imaging, and the potential of adjuvant therapies, particularly pembrolizumab.

Managing Long-Term Toxicities of Combination Lenvatinib and Pembrolizumab in Advanced RCC

October 27th 2023

Drs Elizabeth Plimack and Robert Motzer discuss the long-term toxicities of combination lenvatinib/pembrolizumab in patients with advanced RCC, highlighting fatigue, GI discomfort, hand-foot syndrome, liver toxicity, thyroid toxicity, and proteinuria.

Dosing Considerations for Combination Lenvatinib and Pembrolizumab in Patients with Advanced RCC

October 20th 2023

Experts detail their approaches to dosing combination lenvatinib and pembrolizumab for patients with advanced RCC, emphasizing individualized treatment for balanced efficacy and toxicity.

Lenvatinib Plus Pembrolizumab for Firstline Treatment of Advanced RCC

October 20th 2023

Elizabeth Plimack, MD, and Robert Motzer, MD, explain their preferences between TKI-IO combination therapies for patients with advanced RCC considering efficacy, side effects, and specific patient factors.

Available Treatment Options for Patients with Advanced RCC

October 13th 2023

Medical oncologists discuss a patient's surprising rapid decline after an initial diagnosis of clear cell RCC, emphasizing the efficacy of combination lenvatinib/pembrolizumab in similar patients.

Patient Profile Presentation: A 65-Year-Old Man with Advanced Clear Cell Renal Cell Carcinoma (RCC)

October 13th 2023

Robert Motzer, MD, presents the patient profile of a 65-year-old man diagnosed with clear cell RCC for discussion.

Dr. Plimack on the Growth of Immunotherapy in Bladder Cancer

March 16th 2018

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the growth of immunotherapy for the treatment of patients with bladder cancer.

Dr. Plimack on Immunotherapy Combinations in Bladder Cancer

February 27th 2018

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses immunotherapy combinations for patients with bladder cancer.

Dr. Plimack Discusses Recent Trials in Kidney Cancer

February 13th 2018

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses recent trials in kidney cancer.

Dr. Plimack Discusses Trials Investigating Apalutamide, Enzalutamide in M0 CRPC

February 9th 2018

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses 2 studies reported at the 2018 Genitourinary Cancers Symposium in patients with nonmetastatic M0 castration-resistant prostate cancer (CRPC).

Dr. Plimack on Choosing a Checkpoint Inhibitor in Bladder Cancer

January 16th 2018

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses choosing a checkpoint inhibitor in bladder cancer.

Dr. Plimack on Second-Line Checkpoint Inhibitors in Bladder Cancer

December 12th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the approved checkpoint inhibitors for the second-line treatment of patients with bladder cancer.

Dr. Plimack on Frontline Checkpoint Inhibitors in Bladder Cancer

November 30th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses checkpoint inhibitors in the frontline setting of bladder cancer.

Dr. Plimack on Strategies for Developing Cure for Locally Advanced Urothelial Carcinoma

September 28th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses strategies for developing cures for patients with locally advanced urothelial carcinoma.

Dr. Plimack on the Challenges With Available Immunotherapies for Bladder Cancer

August 15th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, shares the challenges with the FDA-approved immunotherapy agents for the treatment of patients with bladder cancer.

Dr. Plimack on Combo of Pembrolizumab/Epacodostat in Bladder Cancer

July 27th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the phase Ib trial of epacodostat and pembrolizumab (Keytruda) in patients with urothelial carcinoma.

Dr. Plimack on Frontline Pembrolizumab for Urothelial Carcinoma

July 7th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the KEYNOTE-052 trial investigating pembrolizumab (Keytruda) in the frontline setting for patients with urothelial carcinoma.

Dr. Plimack on KEYNOTE-045 Trial for Pembrolizumab in Urothelial Carcinoma

June 22nd 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the updated findings of the KEYNOTE-045 trial of pembrolizumab (Keytruda) in urothelial carcinoma.

Dr. Plimack on Significance of CheckMate-025 Trial in RCC

November 5th 2016

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses updated findings from the CheckMate-025 trial, which compared the efficacy of nivolumab (Opdivo) with everolimus (Afinitor) in patients with renal cell carcinoma.

Dr. Elizabeth Plimack on Consideration Regarding Nivolumab in RCC

August 23rd 2016